drugset / Press release
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis
2020-09-29 · Arcutis Biotherapeutics, Inc. · original arcutis.com ↗
Print Page RSS Feeds Email
The release as fetched from its publisher. arcutis.com ↗